International Biotechnology (IBT) Competitors GBX 684 +10.00 (+1.48%) (As of 12/20/2024 11:48 AM ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendHeadlinesInsider Trades IBT vs. GSS, FCSS, CGT, FSV, JPE, TRY, IEM, RICA, BRWM, and N91Should you be buying International Biotechnology stock or one of its competitors? The main competitors of International Biotechnology include Genesis Emerging Markets Fund (GSS), Fidelity China Special (FCSS), Capital Gearing (CGT), Fidelity Investment Trust - Fidelity Special Values (FSV), JPMorgan Elect plc - Managed Growth (JPE), TR Property Investment Trust (TRY), Impax Environmental Markets (IEM), Ruffer Investment (RICA), BlackRock World Mining Trust (BRWM), and Ninety One Group (N91). These companies are all part of the "asset management" industry. International Biotechnology vs. Genesis Emerging Markets Fund Fidelity China Special Capital Gearing Fidelity Investment Trust - Fidelity Special Values JPMorgan Elect plc - Managed Growth TR Property Investment Trust Impax Environmental Markets Ruffer Investment BlackRock World Mining Trust Ninety One Group Genesis Emerging Markets Fund (LON:GSS) and International Biotechnology (LON:IBT) are both small-cap finance companies, but which is the better stock? We will contrast the two companies based on the strength of their profitability, valuation, risk, media sentiment, analyst recommendations, institutional ownership, community ranking, earnings and dividends. Is GSS or IBT more profitable? International Biotechnology has a net margin of 75.33% compared to Genesis Emerging Markets Fund's net margin of 0.00%. International Biotechnology's return on equity of 6.25% beat Genesis Emerging Markets Fund's return on equity.Company Net Margins Return on Equity Return on Assets Genesis Emerging Markets FundN/A N/A N/A International Biotechnology 75.33%6.25%3.57% Do insiders & institutionals hold more shares of GSS or IBT? 45.2% of International Biotechnology shares are owned by institutional investors. 4.2% of International Biotechnology shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media favor GSS or IBT? In the previous week, International Biotechnology had 3 more articles in the media than Genesis Emerging Markets Fund. MarketBeat recorded 3 mentions for International Biotechnology and 0 mentions for Genesis Emerging Markets Fund. International Biotechnology's average media sentiment score of 1.74 beat Genesis Emerging Markets Fund's score of 0.00 indicating that International Biotechnology is being referred to more favorably in the news media. Company Overall Sentiment Genesis Emerging Markets Fund Neutral International Biotechnology Very Positive Which has preferable earnings and valuation, GSS or IBT? International Biotechnology has lower revenue, but higher earnings than Genesis Emerging Markets Fund. Genesis Emerging Markets Fund is trading at a lower price-to-earnings ratio than International Biotechnology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGenesis Emerging Markets Fund£250.40M0.00N/A£140.70N/AInternational Biotechnology£24.14M10.47£18.19M£0.481,425.00 Does the MarketBeat Community believe in GSS or IBT? International Biotechnology received 74 more outperform votes than Genesis Emerging Markets Fund when rated by MarketBeat users. Likewise, 77.71% of users gave International Biotechnology an outperform vote while only 62.00% of users gave Genesis Emerging Markets Fund an outperform vote. CompanyUnderperformOutperformGenesis Emerging Markets FundOutperform Votes6262.00% Underperform Votes3838.00% International BiotechnologyOutperform Votes13677.71% Underperform Votes3922.29% Is GSS or IBT a better dividend stock? Genesis Emerging Markets Fund pays an annual dividend of GBX 0.17 per share. International Biotechnology pays an annual dividend of GBX 29 per share and has a dividend yield of 4.2%. Genesis Emerging Markets Fund pays out 0.1% of its earnings in the form of a dividend. International Biotechnology pays out 6,041.7% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. SummaryInternational Biotechnology beats Genesis Emerging Markets Fund on 11 of the 14 factors compared between the two stocks. Ad Investors AlleyCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69% dividend from Tesla… Which could put up to $7,013 in your pocket every month…Click here to discover the new #1 way to invest in Tesla Get International Biotechnology News Delivered to You Automatically Sign up to receive the latest news and ratings for IBT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IBT vs. The Competition Export to ExcelMetricInternational BiotechnologyAsset Management IndustryFinancial SectorLON ExchangeMarket Cap£252.81M£1.08B£3.73B£1.90BDividend Yield4.39%4.69%4.43%5.45%P/E Ratio1,425.00802.15418.741,861.10Price / Sales10.471,450.201,744.90392,379.48Price / Cash155.7464.4752.5328.59Price / Book0.911.141.372.80Net Income£18.19M£64.95M£361.47M£155.77M7 Day Performance-3.12%-1.95%-1.62%-2.02%1 Month Performance-0.29%-0.25%0.23%21.62%1 Year Performance11.76%7.20%9.87%29.68% International Biotechnology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IBTInternational BiotechnologyN/AGBX 684+1.5%N/A+13.2%£252.81M£24.14M1,425.00N/AInsider TradePositive NewsGSSGenesis Emerging Markets FundN/AGBX 869-1.0%N/AN/A£1.06B£250.40M6.181,626Gap DownFCSSFidelity China SpecialN/AGBX 216.50-2.0%N/A+6.1%£1.03BN/A4,420.00N/APositive NewsCGTCapital GearingN/AGBX 4,790+0.1%N/A+2.7%£1.02B£-9,860,000.00-7,595.24N/AFSVFidelity Investment Trust - Fidelity Special ValuesN/AGBX 315-0.6%N/A+12.0%£1.02B£11.88M-31,700.0025,000JPEJPMorgan Elect plc - Managed GrowthN/AGBX 937.50flatN/AN/A£1.00B£104.78M1,250.00N/ATRYTR Property Investment TrustN/AGBX 308-0.6%N/A-11.3%£977.44M£-528,720,000.00-175.0426News CoveragePositive NewsHigh Trading VolumeIEMImpax Environmental MarketsN/AGBX 381-0.4%N/A-5.1%£956.62M£1.57M-9,600.00N/ANews CoveragePositive NewsRICARuffer InvestmentN/AGBX 272.50flatN/A+0.2%£945.68M£19.58M9,083.33N/AInsider TradeNews CoverageBRWMBlackRock World Mining TrustN/AGBX 485.50-1.4%N/A-16.1%£928.18M£8.72M-7,007.74147,000News CoverageN91Ninety One Group0.6293 of 5 starsGBX 151.20-1.2%GBX 173+14.4%-18.7%£912.66M£588.50M850.001,180 Related Companies and Tools Related Companies Genesis Emerging Markets Fund Competitors Fidelity China Special Competitors Capital Gearing Competitors Fidelity Investment Trust - Fidelity Special Values Competitors JPMorgan Elect plc - Managed Growth Competitors TR Property Investment Trust Competitors Impax Environmental Markets Competitors Ruffer Investment Competitors BlackRock World Mining Trust Competitors Ninety One Group Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (LON:IBT) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersThis Crypto Is Set to Explode in DecemberIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredYour bank is lying to you.You might think you have your money in a high-yield savings account, but do you really? The national average A...MyBankTracker | SponsoredRare "crisis signal" triggers for third time in U.S. marketA rare pattern has just repeated for the third time in U.S. history. The last two times this happened, the...Stansberry Research | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | SponsoredBuffett's Oil Bet + This 22% Dividend PlayWarren Buffett has been quietly amassing a massive position in oil stocks. But while Buffett's picks (Occid...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding International Biotechnology Please log in to your account or sign up in order to add this asset to your watchlist. Share International Biotechnology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IBT Stock Alerts